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Clinical attempts to reduce the cardiotoxicity of arsenic trioxide (ATO) without compromising its anticancer activities remain to
be an unresolved issue. In this study, we determined whether Sal B can protect against ATO-induced cardiac toxicity in vivo and
increase the toxicity of ATO toward cancer cells. Combination treatment of Sal B and ATO was investigated using BALB/c mice
and human hepatoma (HepG2) cells and human cervical cancer (HeLa) cells. The results showed that the combination treatment
significantly improved the ATO-induced loss of cardiac function, attenuated damage of cardiomyocytic structure, and suppressed
the ATO-induced release of cardiac enzymes into serum in BALB/c mouse models. The expression levels of Bcl-2 and p-Akt in
the mice treated with ATO alone were reduced, whereas those in the mice given the combination treatment were similar to those
in the control mice. Moreover, the combination treatment significantly enhanced the ATO-induced cytotoxicity and apoptosis of
HepG2 cells and HeLa cells. Increases in apoptotic marker cleaved poly (ADP-ribose) polymerase and decreases in procaspase-3
expressions were observed through western blot. Taken together, these observations indicate that the combination treatment of Sal
B and ATO is potentially applicable for treating cancer with reduced cardiotoxic side effects.
1. Introduction
Arsenic trioxide (ATO) was discovered more than 2000
years ago for treating diseases such as cancer, syphilis,
and tuberculosis [1]. Recently, ATO has been recognized
as a clinically effective drug for treating acute promyelo-
cytic leukemia (APL) [2]. However, this treatment was also
associated with QT prolongation, torsades de pointes, and
sudden death [3–5], thereby restricting its broad application.
The possible mechanisms of ATO-induced cardiotoxicity
include DNA fragmentation, reactive oxygen species (ROS)
generation, cardiac ion channel changes, and apoptosis [6–
8]. Although the exact mechanism of ATO cardiotoxicity is
not currently known, the generation of ROS is very common
in arsenic toxicity [8, 9].Therefore, antioxidative agents could
provide an alternative approach to treatATO-induced cardiac
damages.
Salvianolic acid B (Sal B), the most abundant and bioac-
tive member of the salvianolic acids in Salvia miltiorrhiza
[10], has strong antioxidant and free radical scavenging
activities. It is a major component of the commercial Fufang
Danshen products, such as the Compound Danshen Drip-
ping Pill, the Danshen Pian, and the Danshen Injection, used
for the treatment of coronary heart disease, angina pectoris,
and other heart diseases [11, 12]. The cardioprotective prop-
erties of Sal B are partly attributed to its antioxidant and
antiapoptotic effects [13, 14]. We previously demonstrated
that Sal B can ameliorate ATO-induced cardiac cell injury
2 Evidence-Based Complementary and Alternative Medicine
in vitro by preventing ATO-induced excessive intracellular
ROS and cardiomyocyte apoptosis [15]. This finding has
prompted us to investigate whether Sal B can protect against
ATO-induced adverse effects in vivo without changing the
anticancer activity of ATO.
In this work, we examined the effect of an ATO and Sal
B combination treatment on the development of cardiotoxic
side effects in vivo using a mouse model. We then examined
the combination treatment in vitro on human hepatoma
(HepG2) cells and human cervical cancer (HeLa) cells.
The results demonstrated that the combination treatment
eliminated the cardiotoxic side-effects of ATO and enhanced
ATO anticancer activities against HepG2 and HeLa cells in
vitro.
2. Materials and Methods
2.1. Chemicals and Materials. Sal B (>98% purity) was pur-
chased from Shanghai Winherb Medical S & T Development
Co., Ltd., (Shanghai, China). ATO was purchased from
Harbin Yi-da Pharmaceutical Ltd., (Harbin, China). HepG2
and HeLa cells were obtained from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China). Dulbecco’s
modified Eagle’s medium (DMEM) and fetal bovine serum
(FBS) were purchased from Gibco BRL (Grand Island, NY,
USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Sigma-Aldrich (St.
Louis, MO, USA). Annexin V/propidium iodide (PI) apop-
tosis detection kit was obtained from Invitrogen (Eugene,
USA). Kits for determining total creatine kinase (CK), aspar-
tate aminotransferase (AST), lactate dehydrogenase (LDH),
catalase (CAT) activity, glutathione peroxidase (GSH-Px)
activity, and superoxide dismutase (SOD) activity were
obtained from Jiancheng Bioengineering Institute (Nan-
jing, China). The primary antibodies against poly (ADP-
ribose) polymerase (PARP), procaspase-3, Bcl-2, Bax, p-Akt,
and Akt were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The 𝛽-actin primary antibodies and
horseradish-peroxidase-(HRP-)conjugated secondary anti-
bodies were purchased fromCWBiotech (Beijing, China). All
chemical reagents were of analytical grade and commercially
available.
2.2. Animals. Male BALB/c mice weighing from 18 g to 20 g
were purchased from Beijing Vital River Laboratory Animal
Technology Co., Ltd., Beijing, China. The animals were
housed under standard laboratory conditions (25∘C± 1∘C
temperature, 60% humidity, and 12 h photoperiod) and given
free access to sterile food and water. All procedures were per-
formed in accordance with the China Physiological Society
“Guiding Principles in the Care and Use of Animals” and
with the approval of the LaboratoryAnimal ethicsCommittee
of Institute of Medicinal Plant Development, Peking Union
Medical College.
2.3. Experimental Protocols. A total of 60 mice were ran-
domly assigned to four groups: control (10mL/kg saline),
ATO-treated (1mg/kg ATO), ATO and Sal B combination-
treated (2mg/kg Sal B 1 h before ATO administration), and
Sal B treated (2mg/kg Sal B). All treatments were injected via
the tail vein for 2 weeks.
2.4. Echocardiography for Cardiac Functional Analysis. Car-
diac function was analyzed using echocardiography 24 h
after drug treatment. The mice were anesthetized using
from 1.5% to 2% isoflurane, and M-mode ultrasound images
were obtained using a Vevo 770 micro-ultrasound system
(VisualSonics, Toronto, ON, Canada).
2.5. Plasma Collection and Biochemical Determination. After
the completion of the echocardiography, blood samples were
obtained from the inner canthus using a capillary tube under
chloral hydrate anesthesia. The samples were centrifuged at
3000×g for 15min within 1 h after collection. The activities
of LDH, CK, AST, GSH-PX, CAT, and SOD in the plasma
were determined using commercially available kits purchased
from Jiancheng Bioengineering Institute (Nanjing, China)
according to the manufacturer’s instructions.
2.6. Histopathology. The apex of the heart was fixed in
10% formalin, routinely processed, and then embedded in
paraffin. Paraffin sections (3mm) were placed on glass slides,
stainedwith hematoxylin and eosin (HE), and then examined
under a lightmicroscope (CKX41, Olympus, Tokyo, Japan) by
a pathologist blinded to the groups studied.
2.7. Cell Culture and Treatment. HepG2 and HeLa cells
were obtained from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China). The cells were cultured
in DMEM supplemented with 10% (v/v) FBS, 2mM L-
glutamine, 100U/mL penicillin, and 100𝜇g/mL streptomycin
and maintained in a humidified incubator with 95% air and
5% CO
2
at 37∘C. The cells were subcultured after reaching
from 70% to 80% of confluence. In all experiments, the
cells were plated at an appropriate density according to
the experimental design and were grown for 36 h before
experimentation. The optimal doses of Sal B and Sal B
and ATO combination treatment were determined in our
preliminary study (see Supplementary Data 4). Four sets of
experimentswere performed: (1) control cells; (2) cells treated
with ATO (4𝜇M) for 48 h; (3) cells treated with Sal B alone
(10 𝜇M) for 48 h; and (4) cells cotreated with 4 𝜇M ATO and
10 𝜇M Sal B for 48 h.
2.8. Cell Viability Analysis. Cell viability was determined
using MTT assay. Briefly, HepG2 or HeLa cells were seeded
on 96-well plates at a density of 5 × 103 cells/well. The cells
were treated for 48 h with ATO alone (4𝜇M), Sal B alone
(10 𝜇M), or in combination (4 𝜇M ATO and 10 𝜇M Sal B).
Subsequently, the wells added with 20𝜇L MTT (5mg/mL)
were incubated for 4 h. The medium was removed, and the
formazan crystals were dissolved in DMSO. Absorbance was
read at 570 nm on a microplate reader (MQX 200, BioTek
Instruments, Winooski, VT, USA).
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Figure 1: Effects of Sal B and ATO on cardiac dysfunction. Mice were treated with saline or ATO with or without Sal B pretreatment.
Echocardiography was performed after 2 weeks. (a) Representative M-mode echocardiograms were shown. (b) Changes in ejection fraction
(EF), fractional shortening (FS), left ventricular internal diameter at diastole (LVIDd), and left ventricular internal diameter at systole (LVIDs)
in the four groups. Values (𝑛 = 15 per group) are expressed as means± SD. ∗𝑃 < 0.05 versus control; #𝑃 < 0.05 versus ATO-treated mice.
2.9. Annexin V-FITC/PI Apoptosis Assay. The percentage of
early apoptosis and necrosis was measured using an Annexin
V-FITC/PI apoptosis kit for flow cytometry according to
themanufacturer’s instructions (Invitrogen). After treatment,
the cells were harvested, washed twice with cold phosphate-
buffered saline (PBS), and then incubated with 5𝜇L FITC-
Annexin V and 1 𝜇L PI working solution (100 𝜇g/mL) for
15min in the dark at room temperature. Cellular fluorescence
wasmeasured by flow cytometry analysis using a flowcytome-
ter (FACS Calibur, BD Biosciences, CA, USA).
2.10. Western Blot Analysis. After the designated treatment,
heart tissue or HepG2 and HeLa cells were lysed for 30min
on ice with T-PER Tissue or Cell Protein Extraction Reagent
(Pierce Chemical Co., Rockford, IL, USA) containing 1%
phenylmethylsulfonylfluoride. A clear lysate was obtained
through centrifugation at 12000×g for 15min at 4∘C. The
supernate was collected. Protein concentration was deter-
mined through bicinchoninic acid assay. Equal amounts of
lysates (10 𝜇g) were fractionated using 10% sodium dode-
cyl sulfate polyacrylamide gel and electrotransferred onto
nitrocellulose membranes. The membranes were blocked
for 1 h in 5% skim milk and incubated overnight at 4∘C
with the primary antibodies. The membranes were washed
for 30min and then incubated with HRP-conjugated sec-
ondary antibodies for 1 h at room temperature. The mem-
branes were washed for 30min and then visualized using
enhanced chemiluminescence. The protein expression levels
were determined by analyzing the signals captured on the
nitrocellulose membranes using a ChemiDoc image analyzer
(Bio-Rad, USA).
2.11. Statistical Analysis. Data from at least three indepen-
dent experiments were expressed as means± SD. Statistical
comparisons between different groups were measured using
one-way ANOVA followed by the Student-Newman-Keuls
test. The level of significance was set at 𝑃 < 0.05.
3. Results
3.1. Combination Treatment with Sal B and ATODecreases the
Incidence of Cardiotoxic Side Effects Compared with ATO
Treatment Alone in BALB/c Mouse Models
3.1.1. Sal B Attenuates ATO-Induced Cardiac Dysfunction. We
examined the effect of the combination treatment using an in
vivo mouse model of ATO-induced cardiotoxicity. The mice
were treated with ATO and Sal B alone or a combination of
both for 2 weeks, and the results were examined using M-
mode echocardiography (Figure 1(a)). Compared with the
control group, both ejection fraction and fractional short-
ening significantly decreased in the mice administered with
ATO treatment alone but significantly increased in the mice
given the combination treatment (Figure 1(b)). However, no
significant differences were observed in the left ventricular
dimensions at the systole and diastole between the groups.
3.1.2. Sal B Prevents Myocardial Damage. An overall view of
the distribution ofmyocardial damage at the lightmicroscopy
level is shown in Figure 2(a).HE staining of the cardiac tissues
showed clear structural abnormalities, including cytoplasmic
vacuolization, myofibrillar loss, and cardiomyocyte necrosis,
in the ATO-treated hearts compared with the control group.
Structural abnormalities in the ATO-treated hearts were
partly prevented by the combination-treated group. The Sal
B-treated group had normal myocardial morphology.
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Figure 2: Effects of Sal B on ATO-induced myocardial injury in vivo. (a) Effects of Sal B on histological changes in mice hearts by HE
(hematoxylin and eosin) staining (×200). (b) Effects of Sal B on the activities of CK, LDH, GOT, CAT, SOD, and GSH-PX in plasma. Values
(𝑛 = 15 per group) are expressed as means± SD. ∗𝑃 < 0.05 versus control; ∗∗𝑃 < 0.01 versus control; #𝑃 < 0.05 versus ATO-treated
mice; ##𝑃 < 0.01 versus ATO-treated mice. CK: creatine kinase; LDH: lactate dehydrogenase; GOT: glutamic oxaloacetic transaminase; CAT:
catalase; SOD: superoxide dismutase; GSH-PX: glutathione peroxidase.
Next, we measured the levels of serum cardiac enzymes
(CK, AST, and LDH), which are the biomarkers used for
monitoring myocardial damage [16]. Combination treatment
significantly attenuated the ATO-induced increase in serum
cardiac enzyme levels. Sal B treatment alone did not show any
obvious abnormalities compared with the control treatment
(Figure 2(b)).
3.1.3. Sal B Enhances Antioxidant Capacity. As shown in
Figure 2(b), the activities of GSH-PX and SOD in the ATO-
treated group were reduced compared with those in the
control group. However, GSH-PX and SOD activities in the
combination-treated group increased compared with those
in the ATO-treated group. In addition, plasma CAT activity
in the ATO-treated group decreased compared with that
in the control group. This reduction was reversed by the
combination treatment. These findings suggest that Sal B
could considerably improve cellular antioxidative defense
capacity against ATO-induced oxidative stress.
3.1.4. Sal B Increases the Expression of Prosurvival Proteins
in Heart Tissue. The levels of pAkt and Bcl-2 decreased in
the ATO-treated group but not in the combination-treated
group (Figures 3(a) and 3(b)). By contrast, the Bax level
increased in the ATO-treated group. This increase was not
observed in the combination-treated group, in which the Bax
level was similar to that in the control group. Our results
indicate that the Sal-B-induced upregulation of Akt and Bcl-
2 proteins may be involved in the cardioprotective effects
of the combination treatment. These results confirm that
the combination treatment can promote the expressions of
prosurvival proteins in the heart.
3.2. Combination Treatment Reduces Cell Viability in HepG2
and HeLa Cancer Cell Lines. Through MTT assay, we
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Figure 3: Effects of Sal B treatment on protective protein expressions in heart tissue in vivo. Western blotting was performed on harvested
ventricular tissue from mice after 2 weeks of treatment with ATO, Sal B, or both. (a) Effects of Sal B on Akt phosphorylation. Quantitative
analysis of the ratio of p-Akt to Akt in protein expression was evaluated. (b) Effects of Sal B on Bcl-2 and Bax. Quantitative analysis of the
ratio of Bcl-2 to Bax in protein expression was evaluated. Data are representative of three different experiments. ∗𝑃 < 0.05 versus control;
∗∗
𝑃 < 0.01 versus control; #𝑃 < 0.05 versus ATO-treated mice; ##𝑃 < 0.01 versus ATO-treated mice.
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Figure 4: Effects of Sal B and ATO treatment on the cell viability of
cancer cells. HepG2 andHeLa cells were treated with ATO (4𝜇M) in
the presence or absencewith Sal B (10 𝜇M) for 48 h, respectively. Cell
viability was determined byMTT assay (expressed as the percentage
of control in each cell line). The data are expressed as means± SD
from three independent experiments. ∗∗𝑃 < 0.01 versus control;
#
𝑃 < 0.05 versus ATO-treated cells; ##𝑃 < 0.01 versus ATO-treated
cells.
examined the viability of HepG2 and HeLa cell lines after
treatment with ATO and Sal B alone (4 and 10 𝜇M, resp.) or
a combination of both. As shown in Figure 4, combination-
treated cells had a significantly lower viability than those
cells treated with ATO alone. In the normal H9c2 cell lines,
combination-treated cells had a higher viability than those
cells treatedwithATOalone (see SupplementaryData 3).This
finding indicates that combination treatment may have the
potential to enhance the antitumor effect of ATO.
3.3. Combination Treatment Induces Apoptosis in HepG2 Cells
and HeLa Cells. To analyze the effect of Sal B and ATO
combination treatment on apoptosis, we performed annexin
V/PI flow cytometry. The apoptotic fraction in the ATO
and Sal B combination-treated group significantly increased
compared with that in the ATO-group or Sal B-treated
group in HepG2 and HeLa cells (Figures 5(a) and 5(b)). The
results indicate that the combination treatment can cause
considerably higher apoptosis in cancer cells than ATO or Sal
B alone at the tested concentrations.
3.4. Combination-Treatment-Induced Apoptosis Is Caspase
Dependent in HepG2 Cells and HeLa Cells. We tested the
involvement of caspase-3, the major effector of caspase, and
PARP, the main substrate of caspases. Activation of caspase-3
was assessed by the decreased amount of procaspase-3 based
on the western blot analysis [17]. As shown in Figures 6(a)
and 6(b), the levels of procaspase-3 in the ATO and Sal B
combination-treated group significantly decreased compared
to that in the ATO-treated group in both HepG2 cells and
HeLa cells, indicating the enhanced cleavage of procaspase-
3 to its active form. Correspondingly, PARP cleavage was
the most pronounced in the ATO and Sal B combination-
treated group (Figures 6(a) and 6(b)). The results show that
the combination treatment can induce greater acceleration of
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Figure 5: Effects of Sal B on the apoptosis of cancer cells induced by ATO. Annexin V-FITC/PI flow-cytometric data from HepG2 (a) and
HeLa (b) cells treatedwithATO, Sal B, or both (4 𝜇MATO, 10 𝜇MSal B) for 48 h.Thedata are expressed asmeans± SD from three independent
experiments. ∗∗𝑃 < 0.01 versus control; #𝑃 < 0.05 versus ATO-treated cells; ##𝑃 < 0.01 versus ATO-treated cells.
apoptosis in cancer cells than ATO or Sal B alone at the tested
concentrations.
4. Discussion
ATO attracted worldwide attention in the past decade
because of its remarkable efficacy in acute APL [18]. However,
the therapeutic use of ATO is limited by its cardiac toxicity.
Therefore, the development of strategies to reduce these
cardiotoxic effects would allow us to explore the full thera-
peutic potential of ATO, with a substantial impact on cancer
therapy. This study, combined with our previous report [15],
provides evidence that Sal B can protect againstATO-induced
cardiotoxicity and enhance its anticancer activity.
Many reports revealed that Sal B is a promising com-
pound for cardiovascular therapy and may act on multiple
targets, leading to a concerted positive effect [13]. In the
present study, we showed that Sal B significantly prevented
ATO-induced cardiotoxicity. In agreement with several other
studies [7, 19, 20], the underlying mechanism is partly
associated with its cellular antioxidative defense capacity
against ATO-induced oxidative stress, which is a significant
increase in the activities of GSH-PX and SOD in plasma.
These results are also further confirmed by western blot
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Figure 6: Effects of Sal B and ATO treatment on apoptosis-related proteins in vitro. Western blotting was performed onHepG2 (a) andHeLa
(b) cells treated with ATO, Sal B, or both (4𝜇M ATO, 10𝜇M Sal B) for 48 h. The activation of caspase-3 is reflected by the reduced amount
of procaspase-3, and the activation of PARP is reflected by the amount of the cleaved PARP. 𝛽-actin served as an internal control. The data
are expressed as means± SD from three independent experiments. ∗𝑃 < 0.05 versus control; ∗∗𝑃 < 0.01 versus control; #𝑃 < 0.05 versus
ATO-treated cells; ##𝑃 < 0.01 versus ATO-treated cells.
(see Supplementary Data 1). In addition to oxidative dam-
age, our results showed that ATO also caused changes in
cardiac function and increased the levels of serum car-
diac enzymes, whereas Sal B treatment was found to be
effective in preventing ATO-induced alteration in the heart.
Histological studies confirmed that ATO treatment caused
clear physiological changes in the cardiac tissue. However,
Sal B treatment could prevent this change and could also
maintain the cardiac tissue physiologically similar to that of
the normal control. Furthermore, the protective effect of the
combination treatment was also found in the expression of
proteins in the heart. Consistent with the in vitro data [15],
both p-Akt and Bcl-2 levels were significantly reduced in the
ATO-treated group. However, the expression levels of both
proteins were recovered in the combination-treated group.
In cancer cells, however, the effects of the combination are
precisely the opposite (see Supplementary Data 2). These
results suggest that Sal B possesses antioxidant activities and
cardioprotective effects against ATO-induced myocardial
damages.
Another equally important issue is if Sal B could decrease
ATO anticancer activity. Recent studies have demonstrated
that Sal B exhibited significant growth arrest and apoptosis
in many human cancer cell lines, such as head and neck
as well as liver and HL-60, with no apparent toxicity to
noncancerous cells [21, 22]. Notably, reports showed that Sal
B could inhibit CYP1A2 and CYP3A4 mRNA expression and
induce GST protein expression, indicating that Sal B may be
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a protective compound against cancer [23]. In the current
study,we demonstrated that Sal B did not restrain the antipro-
liferative effects of ATO in HepG2 and HeLa cancer cells but
enhanced its antitumor activity. This result is different from
its effects on H9C2 cells. A similar trend was observed in
the percentage of apoptotic cells in the combination-treated
group. We further examined the involvement of caspases in
cotreatment-mediated apoptosis. Compared with the control
group, the expression of procaspase-3 decreased after co-
treatment for 48 h. PARP is the substrate for effector caspases
during apoptosis [24]. PARP cleavage is the hallmark of
apoptosis [24, 25]. Caspase-mediated PARP cleavage showed
that Sal B could increase the sensitivity of HepG2 cells and
HeLa cells towardATOvia caspase pathways. All these results
suggest that Sal B has the potential to be an adjuvant in future
clinical application.
ATO induced apoptosis in both cancer cells and car-
diomyocytes, but Sal B and ATO combination could provide
both cytotoxicity and cardioprotective properties, indicating
that the different effects of Sal B and ATO are dependent on
cell type. These results were also observed in several other
antioxidant studies [7, 26]. Although the mechanism is still
elusive, we speculate that it may be due to the functionally
contradictory effects of some proteins critical for apoptotic
signaling in different cell types induced by ATO, such as the
proapoptotic effects of c-Jun-NH2-kinase (JNK) activation
in ATO-induced ovarian cancer cells [27] in contrast to the
antiapoptotic effects on JNK activation in some other cell
lines [28, 29]. Further studies will be conducted to determine
this mechanism.
In conclusion, we confirmed the protective effects of Sal
B against ATO-induced cardiotoxicity in vivomouse models
in terms of cardiac function, morphological changes, and
antioxidant enzyme activities. A combination treatment of
ATO and Sal B can allow for greater toxicity to cancer cells.
These data support the cardioprotective properties of Sal
B against ATO-induced myocardial toxicity as well as the
enhancement of anticancer activities of ATO, indicating that
the combination of Sal B with ATO has potential clinical
application.
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